Current update on dermatomyositis
Dermatomyositis (DM) is a rare autoimmune disease with involvement of skin and muscle that is classified as an idiopathic inflammatory myopathy. In addition to cutaneous lesions as well as weakness and atrophy of muscles, the heart and lungs are the major affected organs. DM occurs in association wi...
Gespeichert in:
| Veröffentlicht in: | Dermatologie (Heidelberg, Germany) Germany), 2024-02, Vol.75 (2), p.153-162 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | ger |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 162 |
|---|---|
| container_issue | 2 |
| container_start_page | 153 |
| container_title | Dermatologie (Heidelberg, Germany) |
| container_volume | 75 |
| creator | Steininger, Julian Günther, Claudia |
| description | Dermatomyositis (DM) is a rare autoimmune disease with involvement of skin and muscle that is classified as an idiopathic inflammatory myopathy. In addition to cutaneous lesions as well as weakness and atrophy of muscles, the heart and lungs are the major affected organs. DM occurs in association with malignant tumors in 20% of affected adults. The pathogenesis of the disease is not completely understood. DM is a multifactorial disease influenced by genetic, environmental and immunological factors. The immune response is characterized by activation of innate and adaptive immune mechanisms and a strong activation of the type I interferon pathway. Myositis-specific antibodies are characteristic of DM and allow differential diagnosis. Therapies include corticosteroids, antimalarials, immunoglobulins, biologics such as rituximab or JAK inhibitors. Early diagnosis and treatment are essential for the prognosis. |
| doi_str_mv | 10.1007/s00105-023-05273-9 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_2912524569</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2912524569</sourcerecordid><originalsourceid>FETCH-LOGICAL-p567-b0e5feccac02b9c42e6bf72a192e491b2f67c7d155fcb292a86a288b74980f013</originalsourceid><addsrcrecordid>eNo1jztLBDEURoMg7rLuH7CQsbOJ3ty8S1l8wYLN9kOSSWBkXiYzxf57B1yr0xw-zkfIHYMnBqCfCwADSQE5BYmaU3tFtisZ1cD4huxL-QYAjswqI27IhhtmBVi9JQ-HJec4zNUyNW6O1ThUTcy9m8f-PJZ2bsstuU6uK3F_4Y6c3l5Phw96_Hr_PLwc6SSVph6iTDEEFwC9DQKj8kmjYxajsMxjUjrohkmZgkeLziiHxngtrIG0Vu7I49_slMefJZa57tsSYte5IY5LqdEylCiksqt6f1EX38emnnLbu3yu_1_xX4EyTM0</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2912524569</pqid></control><display><type>article</type><title>Current update on dermatomyositis</title><source>MEDLINE</source><source>SpringerNature Journals</source><creator>Steininger, Julian ; Günther, Claudia</creator><creatorcontrib>Steininger, Julian ; Günther, Claudia</creatorcontrib><description>Dermatomyositis (DM) is a rare autoimmune disease with involvement of skin and muscle that is classified as an idiopathic inflammatory myopathy. In addition to cutaneous lesions as well as weakness and atrophy of muscles, the heart and lungs are the major affected organs. DM occurs in association with malignant tumors in 20% of affected adults. The pathogenesis of the disease is not completely understood. DM is a multifactorial disease influenced by genetic, environmental and immunological factors. The immune response is characterized by activation of innate and adaptive immune mechanisms and a strong activation of the type I interferon pathway. Myositis-specific antibodies are characteristic of DM and allow differential diagnosis. Therapies include corticosteroids, antimalarials, immunoglobulins, biologics such as rituximab or JAK inhibitors. Early diagnosis and treatment are essential for the prognosis.</description><identifier>EISSN: 2731-7013</identifier><identifier>DOI: 10.1007/s00105-023-05273-9</identifier><identifier>PMID: 38194097</identifier><language>ger</language><publisher>Germany</publisher><subject>Adrenal Cortex Hormones - therapeutic use ; Adult ; Antibodies ; Dermatomyositis - diagnosis ; Humans ; Myositis - diagnosis ; Skin</subject><ispartof>Dermatologie (Heidelberg, Germany), 2024-02, Vol.75 (2), p.153-162</ispartof><rights>2023. The Author(s), under exclusive licence to Springer Medizin Verlag GmbH, ein Teil von Springer Nature.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38194097$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Steininger, Julian</creatorcontrib><creatorcontrib>Günther, Claudia</creatorcontrib><title>Current update on dermatomyositis</title><title>Dermatologie (Heidelberg, Germany)</title><addtitle>Dermatologie (Heidelb)</addtitle><description>Dermatomyositis (DM) is a rare autoimmune disease with involvement of skin and muscle that is classified as an idiopathic inflammatory myopathy. In addition to cutaneous lesions as well as weakness and atrophy of muscles, the heart and lungs are the major affected organs. DM occurs in association with malignant tumors in 20% of affected adults. The pathogenesis of the disease is not completely understood. DM is a multifactorial disease influenced by genetic, environmental and immunological factors. The immune response is characterized by activation of innate and adaptive immune mechanisms and a strong activation of the type I interferon pathway. Myositis-specific antibodies are characteristic of DM and allow differential diagnosis. Therapies include corticosteroids, antimalarials, immunoglobulins, biologics such as rituximab or JAK inhibitors. Early diagnosis and treatment are essential for the prognosis.</description><subject>Adrenal Cortex Hormones - therapeutic use</subject><subject>Adult</subject><subject>Antibodies</subject><subject>Dermatomyositis - diagnosis</subject><subject>Humans</subject><subject>Myositis - diagnosis</subject><subject>Skin</subject><issn>2731-7013</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo1jztLBDEURoMg7rLuH7CQsbOJ3ty8S1l8wYLN9kOSSWBkXiYzxf57B1yr0xw-zkfIHYMnBqCfCwADSQE5BYmaU3tFtisZ1cD4huxL-QYAjswqI27IhhtmBVi9JQ-HJec4zNUyNW6O1ThUTcy9m8f-PJZ2bsstuU6uK3F_4Y6c3l5Phw96_Hr_PLwc6SSVph6iTDEEFwC9DQKj8kmjYxajsMxjUjrohkmZgkeLziiHxngtrIG0Vu7I49_slMefJZa57tsSYte5IY5LqdEylCiksqt6f1EX38emnnLbu3yu_1_xX4EyTM0</recordid><startdate>202402</startdate><enddate>202402</enddate><creator>Steininger, Julian</creator><creator>Günther, Claudia</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>202402</creationdate><title>Current update on dermatomyositis</title><author>Steininger, Julian ; Günther, Claudia</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p567-b0e5feccac02b9c42e6bf72a192e491b2f67c7d155fcb292a86a288b74980f013</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>ger</language><creationdate>2024</creationdate><topic>Adrenal Cortex Hormones - therapeutic use</topic><topic>Adult</topic><topic>Antibodies</topic><topic>Dermatomyositis - diagnosis</topic><topic>Humans</topic><topic>Myositis - diagnosis</topic><topic>Skin</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Steininger, Julian</creatorcontrib><creatorcontrib>Günther, Claudia</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Dermatologie (Heidelberg, Germany)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Steininger, Julian</au><au>Günther, Claudia</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Current update on dermatomyositis</atitle><jtitle>Dermatologie (Heidelberg, Germany)</jtitle><addtitle>Dermatologie (Heidelb)</addtitle><date>2024-02</date><risdate>2024</risdate><volume>75</volume><issue>2</issue><spage>153</spage><epage>162</epage><pages>153-162</pages><eissn>2731-7013</eissn><abstract>Dermatomyositis (DM) is a rare autoimmune disease with involvement of skin and muscle that is classified as an idiopathic inflammatory myopathy. In addition to cutaneous lesions as well as weakness and atrophy of muscles, the heart and lungs are the major affected organs. DM occurs in association with malignant tumors in 20% of affected adults. The pathogenesis of the disease is not completely understood. DM is a multifactorial disease influenced by genetic, environmental and immunological factors. The immune response is characterized by activation of innate and adaptive immune mechanisms and a strong activation of the type I interferon pathway. Myositis-specific antibodies are characteristic of DM and allow differential diagnosis. Therapies include corticosteroids, antimalarials, immunoglobulins, biologics such as rituximab or JAK inhibitors. Early diagnosis and treatment are essential for the prognosis.</abstract><cop>Germany</cop><pmid>38194097</pmid><doi>10.1007/s00105-023-05273-9</doi><tpages>10</tpages></addata></record> |
| fulltext | fulltext |
| identifier | EISSN: 2731-7013 |
| ispartof | Dermatologie (Heidelberg, Germany), 2024-02, Vol.75 (2), p.153-162 |
| issn | 2731-7013 |
| language | ger |
| recordid | cdi_proquest_miscellaneous_2912524569 |
| source | MEDLINE; SpringerNature Journals |
| subjects | Adrenal Cortex Hormones - therapeutic use Adult Antibodies Dermatomyositis - diagnosis Humans Myositis - diagnosis Skin |
| title | Current update on dermatomyositis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T21%3A16%3A09IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Current%20update%20on%20dermatomyositis&rft.jtitle=Dermatologie%20(Heidelberg,%20Germany)&rft.au=Steininger,%20Julian&rft.date=2024-02&rft.volume=75&rft.issue=2&rft.spage=153&rft.epage=162&rft.pages=153-162&rft.eissn=2731-7013&rft_id=info:doi/10.1007/s00105-023-05273-9&rft_dat=%3Cproquest_pubme%3E2912524569%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2912524569&rft_id=info:pmid/38194097&rfr_iscdi=true |